Whatever else might be said about the recent White Paper, Working for Patients, there is general agreement on the need for a continuing and expanding process of medical audit (also referred to as quality assurance or quality control).' There is a wholly understandable tendency for clinical biochemists (medical and scientific) to consider themselves in the forefront of this field, as exemplified by the constant effort to monitor and improve analytical performance, and by the work spent on defining clinically acceptable levels of analytical performance.' Without any wish to denegrate this work, I suggest that the confidence engendered is misleading.
The final report from a pathology department should be not a set of numbers, but a differential diagnosis. This has recently been discussed by Stewart,' and the Manpower Advisory Service" has expanded on it in its division of pathology services into pre-analytical, analytical and postanalytical phases. Wiener' has illustrated the need for quality assessment in the post-analytical phase by asking for interpretations of the results of glucose tolerance tests-a well-defined situation; and showed that, while most responses were satisfactory, a number did not agree with World Health Organization criteria for the diagnosis of diabetes. Furthermore, 14% of laboratories returned no clinical interpretation even in this study situation and only a third routinely offered any interpretation. The advice given on preparation of patients for the test and the performance of the test itself varied between laboratories. The pre-analytical phase has also been studied by Broughton and Worthington" who found wide variations between laboratories in the range of tests performed in response to common requests. They suggested either local discussion or a consensus approach to reduce the performance of unnecessary tests and improve cost effectiveness.
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philosophy of quality assurance in the analytical phase differs from that in the pre-or post-analytical phases. The emphasis of analytical quality assurance is chiefly aimed towards precision; we hope to achieve accuracy (as judged against a primary standard), but consistent levels of bias or interference do not impair the clinical utility of results. In contrast, accuracy is all-important in clinical work; only the correct diagnosis and the best care are acceptable and consistent clinical decisions are valueless if they are consistently wrong.
The studies referred to above indicate that our performance of the pre-and post-analytical phases could be improved even in the straightforward area of glucose tolerance testing. They show that some laboratories may have paid attention principally to the quality control of analysis to the detriment of the other aspects of pathology. Post-analytical quality control in clinical situations more complex than the glucose tolerance test is likely to prove much more difficult. It should not be overlooked that the correct differential diagnoses, the best management, will vary according to the clinical situation. The Manpower Advisory Service envisaged that the clinical biochemist should be able to help his clinical colleagues (without imposing on their freedom) in such situations. The necessary information should ideally be provided on the request form; but essential information is frequently omitted through oversight or neglect.
It is therefore necessary that we should review our arrangements for clinical liaison, not only to obtain the necessary data but also to maintain the necessary mental outlook to improve our interpretation of each investigation. This outlook will already have been inculcated in those with a medical training; those with a scientific background have shown themselves capable of acquiring it, especially in their fields of special interest. It is also important for us to become involved with our clinical colleagues' arrangements for audit" as it is these, rather than external quality assurance schemes, that are likely to provide the best framework for quality assurance that can relate to every aspect of clinical biochemistry. In addition, the clinical biochemist may be able to make a valuable contribution to clinical audit, by applying expertise in data handling to the field of decision theory. 8 This is an important step for the profession to take now for two main reasons other than quality assessment. First, improved lines of communication between the laboratory and clinicians cannot but be beneficial for patient care.? Secondly, in the present climate, laboratory practice and budgets are being compared one with another with no account taken for local factors.' There is no reason why our practices should not differ, provided that we can justify our actions. Failure to grasp this nettle, beside being detrimental to patients, may result in biochemists who are clinical only in name.
